<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313478302</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313478302</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effects of tetra-arsenic tetra-sulfide on BXSB lupus-prone mice: a pilot study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478302">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wen</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478302">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Qiao</surname><given-names>Z</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313478302">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478302">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sun</surname><given-names>Q</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478302">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478302">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shan</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313478302">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mu</surname><given-names>Z</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478302">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhang</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313478302">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313478302"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203313478302"><label>1</label>Department of Dermatology, Peking University People's Hospital, China</aff>
<aff id="aff2-0961203313478302"><label>2</label>Department of Central Laboratory, Peking University People's Hospital, China</aff>
<aff id="aff3-0961203313478302"><label>3</label>Department of Dermatology, Tianjin Medical University General Hospital, China</aff>
<author-notes>
<corresp id="corresp1-0961203313478302">J Zhang, Department of Dermatology, Peking University People's Hospital No. 11 South Avenue, Xi Zhi Men Street, Xicheng District, Beijing 100044, China. Email: <email>rmzjz@126.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>469</fpage>
<lpage>476</lpage>
<history>
<date date-type="received"><day>31</day><month>8</month><year>2012</year></date>
<date date-type="accepted"><day>17</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Systemic lupus erythematosus (SLE) is an autoimmune disease of uncertain etiology that affects multiple tissues and organs. Arsenic trioxide (ATO) has been used in lupus-prone mice with a regulatory effect on immune abnormality. Tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>), a traditional Chinese medicine, is effective on acute promyelocytic leukemia with mild side effects than ATO. In this study, a pilot study was performed to investigate the effects and the mechanism of As<sub>4</sub>S<sub>4</sub> on the lupus-prone BXSB mice. Improvement of monocytosis (<italic>p</italic> &lt; 0.05) in spleen and decreased serum interleukin-6 (IL-6) (<italic>p</italic> = 0.0277) were observed with As<sub>4</sub>S<sub>4</sub> treatment. As<sub>4</sub>S<sub>4</sub>-treated mice exhibited amelioration of skin, liver and renal disease with mild side effects. Histological analysis revealed that As<sub>4</sub>S<sub>4</sub> suppressed immune complex deposition, mesangial proliferation and inflammatory cell infiltration in kidney and liver. Our study support that As<sub>4</sub>S<sub>4</sub> selectively suppresses cutaneous lupus and nephritis in BXSB mice and might be a potential treatment for SLE.</p>
</abstract>
<kwd-group>
<kwd>Tetra-arsenic tetra-sulfide</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>BXSB mice</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313478302" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a variety of autoantibodies and immune complex (IC) deposition in tissues with multisystemic injuries.<sup><xref ref-type="bibr" rid="bibr1-0961203313478302">1</xref></sup> In the BXSB-strain mouse, a lupus-prone animal, there are iterations of lupus-like symptoms akin to human SLE, including autoantibody production, lymphoid activation and hyperplasia, and some unique histological and serological manifestations were also observed with unique disease accelerators.<sup><xref ref-type="bibr" rid="bibr2-0961203313478302">2</xref></sup> The disease process is strikingly accelerated in male BXSB mice with the Y-accelerating autoimmune gene (Yaa) gene.<sup><xref ref-type="bibr" rid="bibr3-0961203313478302">3</xref></sup></p>
<p>Standard therapy for SLE with glucocorticoids combined with immunosuppressive agents exhibits various side-effects and disease relapses after therapy discontinuation or tapered doses.<sup><xref ref-type="bibr" rid="bibr4-0961203313478302">4</xref></sup> Tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>) has long been used for treatment of leukemia in China. Previous studies exhibited good outcomes in the treatment of both newly diagnosed acute promyelocytic leukemia (APL) and relapsed/refractory promyelocytic leukemia with As<sub>4</sub>S<sub>4</sub> mild toxicity profiles.<sup><xref ref-type="bibr" rid="bibr5-0961203313478302">5</xref></sup> The mechanism involved induction of cell apoptosis.<sup><xref ref-type="bibr" rid="bibr6-0961203313478302">6</xref></sup> To investigate efficacy and side effects, BXSB mice were treated with As<sub>4</sub>S<sub>4</sub> and the clinical effect and immune parameters were studied.</p>
</sec>
<sec id="sec2-0961203313478302" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203313478302"><title>Mice</title>
<p>Male BXSB (H-2<sup>b</sup>) mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA, stock 000740). Male C57BL/6 (H-2<sup>b</sup>) mice were obtained from Unilihua Bioscience Center (Beijing, China). The 28-week-old mice were housed under specific pathogen-free conditions and fed standard rodent chow and water ad libitum. The studies were approved by the Animal Care and Use Committee of Peking University People's Hospital.</p>
</sec>
<sec id="sec4-0961203313478302"><title>Preparation of As<sub>4</sub>S<sub>4</sub> and treatment of animals</title>
<p>As<sub>4</sub>S<sub>4</sub> was kindly provided by Daopei Lu and dissolved in 0.5% methyl cellulose (Sigma-Aldrich, St Louis, Missouri, USA) for the study. As in the Lu et al. study,<sup><xref ref-type="bibr" rid="bibr5-0961203313478302">5</xref></sup> BXSB mice (<italic>n</italic> = 10) were treated with As<sub>4</sub>S<sub>4</sub> 1000 µg/g body weight by oral gavage daily for eight weeks: the control mice (<italic>n</italic> = 10) received the same volume of 0.5% methyl cellulose. C57BL/6 mice (<italic>n</italic> = 5) received 2000 µg/g of As<sub>4</sub>S<sub>4</sub> daily for eight weeks to test toxicity.</p>
</sec>
<sec id="sec5-0961203313478302"><title>Arsenic levels in blood, hair and the complete blood cells count</title>
<p>At scheduled time-points (0, 1, 7, 20 and 60 days after treatment), heparinized blood and hair samples were collected. Quantitative determination of arsenic levels in blood and hair samples was performed as in the previous literature.<sup><xref ref-type="bibr" rid="bibr5-0961203313478302">5</xref></sup> Complete blood cell counts were analyzed with Blood Analyzer (MEK-6318K, Japan) at the end of treatment.</p>
</sec>
<sec id="sec6-0961203313478302"><title>Urinary albumin/creatinine concentration ratios</title>
<p>Mice were placed in metabolic cages for 24 h urine collection. Urinary albumin was determined by use of the Mouse Albumin ELISA Kit (ICL, Newberg, USA) according to the instructions. Urinary creatinine concentrations were detected with a Beckman Auto analyzer (Beckman Coulter, Fullerton, California, USA). Urinary albumin was normalized to creatinine excretion and presented as micrograms of albumin per micromole of creatinine.</p>
</sec>
<sec id="sec7-0961203313478302"><title>Histopathology and immunofluorescence assay</title>
<p>Kidney, liver, lung, ear tissue samples were collected at the time of harvest and fixed in 10% buffered formalin, embedded in paraffin. Hematoxylin and eosin (H&amp;E) or periodic acid-Schiff-methenamine (PASM) stain were formed. For immunofluorescence staining, the kidney tissues were snap-frozen in liquid nitrogen and placed in optimum cutting temperature (OCT) compound (Sakura Japan, Osaka, Japan). Frozen sections (5 µm thick) were stained with fluorescein-conjugated anti-mouse IgG (1:50, AbD serotec, Oxford, UK) or anti-mouse IgM and C3 (1:60 and 1:30, respectively, Cedarlane, Burlington, Canada) and were visualized with a fluorescence microscope.</p>
</sec>
<sec id="sec8-0961203313478302"><title>Lymphoproliferation</title>
<p>The spleens of the mice were harvested and weighed after eight weeks of treatment. Splenomegaly of mice was evaluated by a spleen index (SI) (SI = (spleen weight/body weight) × 1000). The spleens were mashed and passed through a nylon cell strainer (BD Falcon, USA) to prepare a single-cell suspension. The cells were suspended in Roswell Park Memorial Institute (RPMI) 1640 medium with 10% fetal bovine serum and centrifuged: the pelleted cells were resuspended in Lysing Buffer (BD Biosciences, USA) to lyse erythrocytes. After being washed in Phosphate Buffer Solution (PBS) the total number of cells was calculated and used for subsequent experiments.</p>
</sec>
<sec id="sec9-0961203313478302"><title>Flow cytometry</title>
<p>Isolated spleen-cell suspensions were stained with fluorochrome-conjugated monoclonal antibodies against surface/intracellular markers: B cells (B220), T cells (CD90, CD3e, CD4, CD8, FoxP3), monocytes (CD11b), dentritic cells (CD11c), and appropriate isotypic antibodies (purchased from BD PharMingen, San Diego, California, USA) were used as controls. Activated CD4 + T and B cells were defined as CD69 + cells. For detection of the subsets of spleen cells, lymphocyte gates or spleen cell gates were established on the basis of linear FS (forward scatter) and SS (side scatter) to mark out the area in which the majority of such cells resided. A CD4 gate was set to mark out the area in which the majority of CD4 + FoxP3 + cells resided.</p>
<p>The percentage and the absolute number of positive stained cells were analyzed on a FACSCalibur flow cytometer using CellQuest pro software (Becton Dickinson, San Diego, California, USA).</p>
</sec>
<sec id="sec10-0961203313478302"><title>Anti-DNA autoantibodies</title>
<p>Serum samples were collected every four weeks from 28-week-old BXSB mice. Serum anti-dsDNA IgG was measured with commercially available ELISA kits (ADI, San Antonio, USA) according to the manufacturer's instructions.</p>
</sec>
<sec id="sec11-0961203313478302"><title>Cytokines detection</title>
<p>Interleukin-6 (IL-6), IL-10, IFN-γ, TNF-α, IL-12p70 and monocyte chemoattractant protein-1 (MCP-1) was detected using a mouse inflammation cytometric bead array kit (CBA; BD Biosciences, San Diego, California, USA) and was analyzed on a FACSCalibur flow cytometer. Standard curves were determined for each cytokine from a range of 10–5000 pg/ml. The lower limit of detection for the CBA, according to the manufacturer is 2.5–52.7 pg/ml, depended on the analyte.</p>
</sec>
<sec id="sec12-0961203313478302"><title>Statistical analysis</title>
<p>Results were expressed as mean ± standard error (SE). Data analysis was performed using GraphPad Prism 5 version 5.01 software. The <italic>T</italic> test was used to compare the values. The value of <italic>p</italic> &lt; 0.05 was considered as statistically significant.</p>
</sec>
</sec>
<sec id="sec13-0961203313478302" sec-type="results"><title>Results</title>
<sec id="sec14-0961203313478302"><title>Effect of As<sub>4</sub>S<sub>4</sub> treatment on clinical course and manifestations in BXSB mice</title>
<p>Skin lesions manifested as hair loss, erythema and scales on the face and ears which started at the age of 16 weeks. Histological examination revealed hyperkeratosis, epidermal hyperplasia and mononuclear cell infiltration of the dermis (<xref ref-type="fig" rid="fig1-0961203313478302">Figure 1(A)</xref>). The skin lesions improved in BXSB mice treated with 1000 µg/g As<sub>4</sub>S<sub>4</sub> and this was confirmed by histopathologic examination (<xref ref-type="fig" rid="fig1-0961203313478302">Figure 1(B)</xref>). In the control group, three (3/10) mice died at 29 and 30 weeks: one of the treatment group mice died at 30 weeks. One (1/10) mouse developed arthritis with severe joint swelling, and this remitted after two weeks of As<sub>4</sub>S<sub>4</sub> treatment (<xref ref-type="fig" rid="fig1-0961203313478302">Figure 1(C)</xref> and (<xref ref-type="fig" rid="fig1-0961203313478302">D</xref>)).
<fig id="fig1-0961203313478302" position="float"><label>Figure 1</label><caption><p>Tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>) improves established skin and joint lesions in BXSB mice. (A) Representative pictures of skin lesions and histopathology on the ears of BXSB mice before treatment, characterized by erythema and scales. (B) Improvement of skin lesions and histopathology after four weeks of treatment with As<sub>4</sub>S<sub>4</sub>. Light microscopy histology of these skin lesions (Hematoxylin and eosin stained, original magnification × 100). (C) Paw swelling in BXSB mice, and (D) improvement after two weeks treatment with As<sub>4</sub>S<sub>4</sub>.</p></caption><graphic xlink:href="10.1177_0961203313478302-fig1.tif"/>
</fig></p>
</sec>
<sec id="sec15-0961203313478302"><title>Effects of As<sub>4</sub>S<sub>4</sub> treatment on histopathology of liver, lung and kidney in BXSB mice</title>
<p>Tissues of liver, lung and kidney were collected at the end of eight-week administration of As<sub>4</sub>S<sub>4</sub><italic><sub>.</sub></italic> Histological examination exhibited hepatocyte spotty necrosis with lymphocyte and neutrophil infiltration around the portal and hepatic veins, which improved after eight weeks of treatment (<xref ref-type="fig" rid="fig2-0961203313478302">Figure 2(A)</xref> and (<xref ref-type="fig" rid="fig2-0961203313478302">B</xref>)). In C57BL/6 mice treated with 2000 µg/g As<sub>4</sub>S<sub>4</sub>, normal histological manifestation of livers was observed. As<sub>4</sub>S<sub>4</sub> treatment slightly reduced the inflammation of lung disease in BXSB mice without significant difference compared to the control group.
<fig id="fig2-0961203313478302" position="float"><label>Figure 2</label><caption><p>Improvement of liver inflammation in tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>)-treated BXSB mice. Histopathologic findings were obtained in the livers from (A) control and (B) As<sub>4</sub>S<sub>4</sub>-treated 36-week-old BXSB mice (Hematoxylin and eosin stained, original magnification × 100).</p></caption><graphic xlink:href="10.1177_0961203313478302-fig2.tif"/>
</fig></p>
<p>Male BXSB mice develop severe lupus nephritis at 24 weeks of age.<sup><xref ref-type="bibr" rid="bibr7-0961203313478302">7</xref></sup> At 36 weeks of age, kidney histological examination exhibited mesangial proliferation, focal segmental glomerulosclerosis and tubular protein casts (<xref ref-type="fig" rid="fig3-0961203313478302">Figure 3(A)</xref>). As<sub>4</sub>S<sub>4</sub>-treatment improved the change compared to the control group (<xref ref-type="fig" rid="fig3-0961203313478302">Figure 3(B)</xref>). Strong deposition of IgG, IgM and C3 to the mesangium and capillary loop of glomeruli in BXSB mice was significantly inhibited with As<sub>4</sub>S<sub>4</sub> treatment. As<sub>4</sub>S<sub>4</sub>-treatment decreased urinary albumin after four weeks of treatment, which was significant at week 7 (<italic>p</italic> &gt; 0.05, <xref ref-type="fig" rid="fig3-0961203313478302">Figure 3(C)</xref>).
<fig id="fig3-0961203313478302" position="float"><label>Figure 3</label><caption><p>(A,B) Representative periodic acid-Schiff-methenamine (PASM)-stained of renal sections from 36-week-old BXSB. (A) Sections from the control group show glomerulosclerosis, tubular protein cast. (B) Sections from the tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>) treatment groups show normal glomeruli and tubules (original magnification × 20). (C) Urinary albumin/creatinine ratios were determined after treatment of As<sub>4</sub>S<sub>4</sub> (1000 µg/g, <italic>n</italic> = 5). Urinary albumin in As<sub>4</sub>S<sub>4</sub>-treated mice began to lower at four weeks and distinctly at week 7 of treatment.</p></caption><graphic xlink:href="10.1177_0961203313478302-fig3.tif"/>
</fig></p>
</sec>
<sec id="sec16-0961203313478302"><title>Arsenic level in blood and hair</title>
<p>Blood and hair arsenic concentration was measured at day 1, 7, 20 and 60 of As<sub>4</sub>S<sub>4</sub> administration. Arsenic was detectable in blood and hair after 24 h of treatment, and increased to 300.27 ng/ml in blood and 36.07 µg/g in hair on day 20 respectively (<xref ref-type="fig" rid="fig4-0961203313478302">Figure 4(A)</xref> and (<xref ref-type="fig" rid="fig4-0961203313478302">B</xref>)).
<fig id="fig4-0961203313478302" position="float"><label>Figure 4</label><caption><p>Arsenic concentration in blood and hair in BXSB mice treated with tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>) (<italic>n</italic> = 4). (A) and (B) Blood and hair arsenic levels increased during the eight weeks of continued administration of As<sub>4</sub>S<sub>4</sub>.</p></caption><graphic xlink:href="10.1177_0961203313478302-fig4.tif"/>
</fig></p>
</sec>
<sec id="sec17-0961203313478302"><title>Effect of As<sub>4</sub>S<sub>4</sub> on splenomegaly and spleen cell subsets</title>
<p>Splenomegaly was observed in adult BXSB mice. Treatment with As<sub>4</sub>S<sub>4</sub> decreased the splenomegaly (<xref ref-type="fig" rid="fig5-0961203313478302">Figure 5(A)</xref>). The weights of the spleens were 202.2 ± 14.71 mg in As<sub>4</sub>S<sub>4</sub>-treated BXSB mice and 223.22 ± 17.40 mg in control mice (<italic>p</italic> &gt; 0.05). The body weights were 25.28 ± 0.54 g and 22.01 ± 0.86 g respectively (<italic>p</italic> &gt; 0.05). The spleen index (SI) was 7.97 ± 0.55 and 10.32 ± 0.97 in As<sub>4</sub>S<sub>4</sub>-treated BXSB mice and the control group, respectively (<italic>p</italic> = 0.0447) (<xref ref-type="fig" rid="fig5-0961203313478302">Figure 5(B)</xref>). As<sub>4</sub>S<sub>4</sub> treatment showed improvement of splenomegaly, but not a return to normal (<italic>p</italic> &lt; 0.05).
<fig id="fig5-0961203313478302" position="float"><label>Figure 5</label><caption><p>Spleen weights were determined at 36 weeks after eight weeks of treatment. (A) Spleens from 36-week-old BXSB and C57BL/6 mice. (B) Spleen index (SI) was lower in tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>)–treated BXSB mice (SI = (spleen weight/body weight) × 1000, <italic>n</italic> ≥ 5, *<italic>p</italic> &lt; 0.05 compared with control BXSB mice).</p></caption><graphic xlink:href="10.1177_0961203313478302-fig5.tif"/>
</fig></p>
<p>To detect toxicity of As<sub>4</sub>S<sub>4</sub>, spleen cell numbers and blood cell count were determined in BXSB and C57BL/6 mice treated with As<sub>4</sub>S<sub>4</sub> for eight weeks. The total numbers of spleen cells in As<sub>4</sub>S<sub>4</sub>-treated BXSB mice were decreased, but slightly increased in C57BL/6 (<italic>p</italic> &gt; 0.05) (<xref ref-type="table" rid="table1-0961203313478302">Table 1</xref>). WBC were significantly decreased (<italic>p</italic> = 0.0328), and no change was observed in C57BL/6 mice.
<table-wrap id="table1-0961203313478302" position="float"><label>Table 1</label><caption><p>Tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>) effects on spleen cell count and peripheral cell number in BXSB and C57BL/6 mice</p></caption>
<graphic alternate-form-of="table1-0961203313478302" xlink:href="10.1177_0961203313478302-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Spleen cell count (×10<sup>7</sup>)</th>
<th>WBC (×10<sup>9</sup>)</th>
<th>RBC (×10<sup>12</sup>)</th>
<th>PLT (×10<sup>9</sup>)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Control-BXSB</td>
<td>8.140 ± 0.485</td>
<td>14.602 ± 2.72</td>
<td>6.5 ± 0.297</td>
<td>564.6 ± 21.598</td>
</tr>
<tr>
<td>As<sub>4</sub>S<sub>4</sub>-treated BXSB</td>
<td>6.792 ± 0.757</td>
<td>7.7333 ± 1.067<sup><xref ref-type="table-fn" rid="table-fn1-0961203313478302">a</xref></sup></td>
<td>5.635 ± 0.131</td>
<td>548.333 ± 33.734</td>
</tr>
<tr>
<td>Control-C57BL/6</td>
<td>5.538 ± 0.440</td>
<td>13.26 ± 1.3556</td>
<td>7.944 ± 0.214</td>
<td>418.4 ± 11.860</td>
</tr>
<tr>
<td>As<sub>4</sub>S<sub>4</sub>-treated C57BL/6</td>
<td>7.300 ± 1.206</td>
<td>13.54 ± 1.054</td>
<td>7.576 ± 0.391</td>
<td>497.6 ± 34.080</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313478302"><label>a</label><p><italic>p</italic> &lt; 0.05 compared with control BXSB mice (<italic>n</italic> ≥ 5). WBC: white blood cells; RBC: red blood cells; PLT: platelets</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The spleen cell subsets of BXSB mice were measured using flow cytometric analysis. CD11b + cells were reduced both in percentage and absolute number in the As<sub>4</sub>S<sub>4</sub>-treated group (<italic>p</italic> = 0.0339, <italic>p</italic> = 0.0308 respectively). However, there was no significant difference in CD3 + T cells, CD4 + T cells, CD4 + FoxP3 + T cells, CD8 + T cells, B220 + B cells and CD11c + cells between the As<sub>4</sub>S<sub>4</sub>-treated and control groups. The active CD4 + T cells and B cells were slightly lower in As<sub>4</sub>S<sub>4</sub>-treated mice (<italic>p</italic> &gt; 0.05) (<xref ref-type="table" rid="table2-0961203313478302">Table 2</xref>).
<table-wrap id="table2-0961203313478302" position="float"><label>Table 2</label><caption><p>Phenotypes of spleen cells</p></caption>
<graphic alternate-form-of="table2-0961203313478302" xlink:href="10.1177_0961203313478302-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="2">Control-BXSB % Absolute number (×10<sup>5</sup>)</th>
<th colspan="2">As<sub>4</sub>S<sub>4</sub>-treated-BXSB % Absolute number (×10<sup>5</sup>)</th>
</tr></thead>
<tbody align="left">
<tr>
<td>CD3</td>
<td>45.03 ± 1.96</td>
<td>205.96 ± 28.37</td>
<td>37.72 ± 3.02</td>
<td>188.55 ± 16.74</td>
</tr>
<tr>
<td>CD4</td>
<td>27.05 ± 1.70</td>
<td>122.33 ± 16.63</td>
<td>23.02 ± 1.90</td>
<td>115.81 ± 10.62</td>
</tr>
<tr>
<td>CD4CD69</td>
<td>0.66 ± 0.16</td>
<td>0.74 ± 0.22</td>
<td>0.59 ± 0.09</td>
<td>0.73 ± 0.139</td>
</tr>
<tr>
<td>CD4FOXP3</td>
<td>2.77 ± 0.28</td>
<td>3.44 ± 0.68</td>
<td>2.74 ± 0.38</td>
<td>3.23 ± 0.48</td>
</tr>
<tr>
<td>CD8</td>
<td>16.07 ± 1.57</td>
<td>74.48 ± 11.76</td>
<td>13.10 ± 2.06</td>
<td>64.92 ± 9.72</td>
</tr>
<tr>
<td>B220</td>
<td>36.98 ± 3.28</td>
<td>165.92 ± 21.57</td>
<td>35.00 ± 3.50</td>
<td>186.17 ± 25.36</td>
</tr>
<tr>
<td>B220CD69</td>
<td>1.67 ± 0.42</td>
<td>3.08 ± 1.28</td>
<td>1.56 ± 0.17</td>
<td>3.02 ± 0.57</td>
</tr>
<tr>
<td>CD11b</td>
<td>39.66 ± 6.97</td>
<td>333.20 ± 71.40</td>
<td>23.80 ± 1.54<sup><xref ref-type="table-fn" rid="table-fn2-0961203313478302">a</xref></sup></td>
<td>166.50 ± 16.77<sup><xref ref-type="table-fn" rid="table-fn2-0961203313478302">a</xref></sup></td>
</tr>
<tr>
<td>CD11c</td>
<td>4.13 ± 0.50</td>
<td>33.29 ± 3.97</td>
<td>3.71 ± 0.32</td>
<td>25.88 ± 3.15</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203313478302"><label>a</label><p><italic>p</italic> &lt; 0.05 compared with control BXSB mice (<italic>n</italic> ≥ 5).</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec18-0961203313478302"><title>Effect of As<sub>4</sub>S<sub>4</sub> treatment on serum anti-dsDNA antibodies and cytokines</title>
<p>Blood samples were collected at 28, 32 and 36 weeks. As<sub>4</sub>S<sub>4</sub>-treatment decreased the level of anti-dsDNA antibody slightly at the end of treatment, but without a significant difference (<xref ref-type="fig" rid="fig6-0961203313478302">Figure (6)</xref>).
<fig id="fig6-0961203313478302" position="float"><label>Figure 6</label><caption><p>Tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>) has minimal impact on serum anti-dsDNA IgG production in BXSB mice (<italic>n</italic> = 5).</p></caption><graphic xlink:href="10.1177_0961203313478302-fig6.tif"/>
</fig></p>
<p>Serum levels of IL-6, IL-10, MCP-1, IFN-γ, TNF-α and IL-12p70 were analyzed in the BXSB and C57BL/6 mice. In BXSB mice, the IL-6 level was highly elevated (<italic>p</italic> = 0.0229). After treatment with As<sub>4</sub>S<sub>4</sub>, IL-6 reduced significantly (<italic>p</italic> = 0.0277, <xref ref-type="fig" rid="fig7-0961203313478302">Figure (7)</xref>). The levels of IL-10, MCP-1, IFN-γ, TNF-α and IL-12p70 in As<sub>4</sub>S<sub>4</sub> treatment groups were slightly lower than in the control group but the difference was not significant.
<fig id="fig7-0961203313478302" position="float"><label>Figure 7</label><caption><p>Serum cytokines level in BXSB mice treated with placebo or Tetra-arsenic tetra-sulfide (As<sub>4</sub>S<sub>4</sub>) (1000 µg/g) for eight weeks. Note that As<sub>4</sub>S<sub>4</sub> reduced the IL-6 level in serum. (<italic>n</italic> = 5, *<italic>p</italic> &lt; 0.05 compared with control BXSB mice).</p></caption><graphic xlink:href="10.1177_0961203313478302-fig7.tif"/>
</fig></p>
</sec>
</sec>
<sec id="sec19-0961203313478302" sec-type="discussion"><title>Discussion</title>
<p>As<sub>4</sub>S<sub>4</sub>, the major ingredient of realgar, has long been used in Chinese medicine for treatment of various diseases.<sup><xref ref-type="bibr" rid="bibr8-0961203313478302">8</xref></sup> In 1994, Lu et al.<sup><xref ref-type="bibr" rid="bibr5-0961203313478302">5</xref></sup> administered an oral preparation of highly purified As<sub>4</sub>S<sub>4</sub> for the treatment of APL, and found support that it is effective on both remission induction and maintenance therapy for all stages of aPL with mild side effects. These findings give As<sub>4</sub>S<sub>4</sub> an advantage over ATO in maintenance treatment. Previous studies reported that ATO was an effective agent for autoimmune disease treatment.<sup><xref ref-type="bibr" rid="bibr9-0961203313478302">9</xref>,<xref ref-type="bibr" rid="bibr10-0961203313478302">10</xref></sup> However, it is uncertain whether As<sub>4</sub>S<sub>4</sub> had the same therapeutic effect as in those studies.</p>
<p>In our preliminary animal study, As<sub>4</sub>S<sub>4</sub> showed efficacy with a dose of 1000 µg/g. In the present study, the effects of As<sub>4</sub>S<sub>4</sub> on histology change, lymphocyte subsets, serum autoantibody and cytokines levels in BXSB mice were determined. The results suggested that oral As<sub>4</sub>S<sub>4</sub> with the daily dose of 1000 µg/g could alleviate splenomegaly, skin lesions, liver lesions and nephritis. The monocytosis in BXSB mice was inhibited with a decreased level of IL-6. The treatment was tolerated well with mild adverse effects.</p>
<p>As<sub>4</sub>S<sub>4</sub> is absorbed in minor amounts into the serum, where it mainly binds to sulfhydryl protein and other small molecules such as glutathione and cysteine, and is transported to various tissues and organs. It also binds to keratin and can be removed through hair, nail growth and cutaneous surfaces.<sup><xref ref-type="bibr" rid="bibr11-0961203313478302">11</xref></sup> In this study, As<sub>4</sub>S<sub>4</sub> concentration in plasma and hair increased after 24 h of treatment, and matched the treatment process, which suggested that the administration was effective.</p>
<p>Monocytosis might play an important role in the disease development of BXSB mice.<sup><xref ref-type="bibr" rid="bibr12-0961203313478302">12</xref><xref ref-type="bibr" rid="bibr13-0961203313478302"/><xref ref-type="bibr" rid="bibr14-0961203313478302"/><xref ref-type="bibr" rid="bibr15-0961203313478302"/>–<xref ref-type="bibr" rid="bibr16-0961203313478302">16</xref></sup> Our data revealed severe monocytosis developed (approximately 40% in the spleen), and decreased significantly after As<sub>4</sub>S<sub>4</sub> treatment. The result suggests that arsenic might play a pivotal role in cell apoptosis induction and autophagy, through which monocytes were the major target.<sup><xref ref-type="bibr" rid="bibr17-0961203313478302">17</xref><xref ref-type="bibr" rid="bibr18-0961203313478302"/>–<xref ref-type="bibr" rid="bibr19-0961203313478302">19</xref></sup></p>
<p>As<sub>4</sub>S<sub>4</sub> treatment improved glomerulonephritis in the BXSB kidney, confirmed by the decreased intensity of IgG, C3 and IgM deposition and the lower albumin in urine. However, the outcomes were not matched by the decrease of serum levels of anti-dsDNA antibodies. The results support the paradigm that anti-dsDNA antibody plays a major role in lupus nephritis and does not correlate with renal pathology in lupus-prone mice.<sup><xref ref-type="bibr" rid="bibr20-0961203313478302">20</xref></sup></p>
<p>The liver is rarely involved in SLE patients (about 3–5%).<sup><xref ref-type="bibr" rid="bibr21-0961203313478302">21</xref>,<xref ref-type="bibr" rid="bibr22-0961203313478302">22</xref></sup> Andrew et al.<sup><xref ref-type="bibr" rid="bibr3-0961203313478302">3</xref></sup> reported that only one out of 20 BXSB mice developed cirrhosis at 12 ∼ 20 weeks old. A recent study indicated that Fas (TNF receptor superfamily member 6) and mitochondria dependent apoptosis increased in the livers of NZB/W F1 mice.<sup><xref ref-type="bibr" rid="bibr23-0961203313478302">23</xref></sup> In our study, most BXSB mice developed hepatic histology at 36 weeks old. As<sub>4</sub>S<sub>4</sub> reduced the liver inflammation of BXSB mice. It is known that ATO can cause severe liver damage, so we evaluated the liver toxicity of As<sub>4</sub>S<sub>4</sub> in C57BL/6 mice. The result showed no obvious hepatotoxicity of As<sub>4</sub>S<sub>4</sub> at the dose of 2000 µg/g. This is consistent with the result of mild and transient hepatotoxicity of As<sub>4</sub>S<sub>4</sub> treatment in patients with aPL.<sup><xref ref-type="bibr" rid="bibr5-0961203313478302">5</xref></sup></p>
<p>Extensive cytokine dysregulation was demonstrated in BXSB mice.<sup><xref ref-type="bibr" rid="bibr24-0961203313478302">24</xref></sup> In our study, serum levels of IL-6, IL-10, IL-12p70, IFN-γ, and TNF-α were detected. High levels of IL-6 were determined. IL-6 is a pleiotropic cytokine synthesized predominantly by macrophages and monocytes and involved in human lupus nephritis.<sup><xref ref-type="bibr" rid="bibr25-0961203313478302">25</xref>,<xref ref-type="bibr" rid="bibr26-0961203313478302">26</xref></sup> The significant decrease of IL-6 after As<sub>4</sub>S<sub>4</sub> treatment was associated with the reduction of infiltrating macrophages in the kidney and decrease in renal IgG and C3 deposition.<sup><xref ref-type="bibr" rid="bibr27-0961203313478302">27</xref></sup> These results indicate that IL-6 is a key factor in glomerulonephritis in lupus. As<sub>4</sub>S<sub>4</sub> treatment contributed to this therapeutic effect.</p>
<p>BXSB mice are considered to be B cell-dominant in the development of autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr28-0961203313478302">28</xref></sup> No significant effect of As<sub>4</sub>S<sub>4</sub> on B cells was observed in BXSB mice in our study. The outcomes suggest that monocytes might be involved in the pathogenesis of lupus in BXSB mice. These results are consistent with a prior report on monocytosis as strongly associated with autoantibody production and subsequent development of lupus nephritis.<sup><xref ref-type="bibr" rid="bibr15-0961203313478302">15</xref></sup> However, As<sub>4</sub>S<sub>4</sub> did not affect lung disease in BXSB mice. The more likely possibility is that pathomechanism of individual end organs may not be as uniform, which confirms previous reports that had found dissociated outcomes for lung disease and other disease manifestations in lupus-prone mice.<sup><xref ref-type="bibr" rid="bibr29-0961203313478302">29</xref>,<xref ref-type="bibr" rid="bibr30-0961203313478302">30</xref></sup></p>
<p>This pilot study demonstrated the efficacy of As<sub>4</sub>S<sub>4</sub> on autoimmune disease in BXSB mice. Clinically, As<sub>4</sub>S<sub>4</sub> inhibited skin, kidney and liver involvements. Experimental study revealed that it decreased monocytosis and IL-6 production. No obvious side effect or toxicity was observed. The mechanism may overlap with, but not be identical to, that involved in the treatment of malignancies such as aPL, and needs further study to elucidate.</p>
</sec>
</body>
<back>
<sec id="sec20-0961203313478302"><title>Funding</title>
<p>This study was supported by the Natural Science Foundation of China (No. 81071296) and the Beijing Natural Science Foundation (No. 7102156).</p>
</sec>
<sec id="sec21-0961203313478302"><title>Conflict of Interest Statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>The authors wish to express their gratitude to Professor Daopei Lu for his generous offer of As<sub>4</sub>S<sub>4</sub>.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313478302"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>JA</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>1994</year>; <volume>330</volume>: <fpage>1871</fpage>–<lpage>1879</lpage>.</citation></ref>
<ref id="bibr2-0961203313478302"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>D</given-names></name><name><surname>Sang</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Murine models of systemic lupus erythematosus</article-title>. <source>J Biomed Biotechnol</source> <year>2011</year>; <volume>2011</volume>: <fpage>1</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr3-0961203313478302"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>BS</given-names></name><name><surname>Eisenberg</surname><given-names>RA</given-names></name><name><surname>Theofilopoulos</surname><given-names>AN</given-names></name><etal/></person-group>. <article-title>Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains</article-title>. <source>J Exp Med</source> <year>1978</year>; <volume>148</volume>: <fpage>1198</fpage>–<lpage>1215</lpage>.</citation></ref>
<ref id="bibr4-0961203313478302"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karim</surname><given-names>MY</given-names></name><name><surname>Pisoni</surname><given-names>CN</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name></person-group>. <article-title>Update on immunotherapy for systemic lupus erythematosus–what's hot and what's not!</article-title>. <source>Rheumatology (Oxford)</source> <year>2009</year>; <volume>48</volume>: <fpage>332</fpage>–<lpage>341</lpage>.</citation></ref>
<ref id="bibr5-0961203313478302"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>DP</given-names></name><name><surname>Qiu</surname><given-names>JY</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: A pilot report</article-title>. <source>Blood</source> <year>2002</year>; <volume>99</volume>: <fpage>3136</fpage>–<lpage>3143</lpage>.</citation></ref>
<ref id="bibr6-0961203313478302"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Comparative proteome study of apoptosis induced by As<sub>4</sub>S<sub>4</sub> in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells</article-title>. <source>Leuk Res</source> <year>2010</year>; <volume>34</volume>: <fpage>1506</fpage>–<lpage>1516</lpage>.</citation></ref>
<ref id="bibr7-0961203313478302"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theofilopoulos</surname><given-names>AN</given-names></name><name><surname>Dixon</surname><given-names>FJ</given-names></name></person-group>. <article-title>Etiopathogenesis of murine SLE</article-title>. <source>Immunol Rev</source> <year>1981</year>; <volume>55</volume>: <fpage>179</fpage>–<lpage>216</lpage>.</citation></ref>
<ref id="bibr8-0961203313478302"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Mineral arsenicals in traditional medicines: Orpiment, realgar, and arsenolite</article-title>. <source>J Pharmacol Exp Ther</source> <year>2008</year>; <volume>326</volume>: <fpage>363</fpage>–<lpage>368</lpage>.</citation></ref>
<ref id="bibr9-0961203313478302"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bobe</surname><given-names>P</given-names></name><name><surname>Bonardelle</surname><given-names>D</given-names></name><name><surname>Benihoud</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice</article-title>. <source>Blood</source> <year>2006</year>; <volume>108</volume>: <fpage>3967</fpage>–<lpage>3975</lpage>.</citation></ref>
<ref id="bibr10-0961203313478302"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>XR</given-names></name><name><surname>Lin</surname><given-names>SX</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name></person-group>. <article-title>Effects of arsenic trioxide on the autoimmunity and survival time in BXSB lupus mice</article-title>. <source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source> <year>2007</year>; <volume>27</volume>: <fpage>138</fpage>–<lpage>141</lpage>.</citation></ref>
<ref id="bibr11-0961203313478302"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindgren</surname><given-names>A</given-names></name><name><surname>Vahter</surname><given-names>M</given-names></name><name><surname>Dencker</surname><given-names>L</given-names></name></person-group>. <article-title>Autoradiographic studies on the distribution of arsenic in mice and hamsters administered 74As-arsenite or -arsenate</article-title>. <source>Acta Pharmacol Toxicol (Copenh)</source> <year>1982</year>; <volume>51</volume>: <fpage>253</fpage>–<lpage>265</lpage>.</citation></ref>
<ref id="bibr12-0961203313478302"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wofsy</surname><given-names>D</given-names></name><name><surname>Kerger</surname><given-names>CE</given-names></name><name><surname>Seaman</surname><given-names>WE</given-names></name></person-group>. <article-title>Monocytosis in the BXSB model for systemic lupus erythematosus</article-title>. <source>J Exp Med</source> <year>1984</year>; <volume>159</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</citation></ref>
<ref id="bibr13-0961203313478302"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>NJ</given-names></name><name><surname>Gabriel</surname><given-names>L</given-names></name><name><surname>Nunes</surname><given-names>CT</given-names></name><etal/></person-group>. <article-title>Monocytosis in BXSB mice is due to epistasis between Yaa and the telomeric region of chromosome 1 but does not drive the disease process</article-title>. <source>Genes Immun</source> <year>2007</year>; <volume>8</volume>: <fpage>619</fpage>–<lpage>627</lpage>.</citation></ref>
<ref id="bibr14-0961203313478302"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merino</surname><given-names>R</given-names></name><name><surname>Fossati</surname><given-names>L</given-names></name><name><surname>Lacour</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>H-2-linked control of the Yaa gene-induced acceleration of lupus-like autoimmune disease in BXSB mice</article-title>. <source>Eur J Immunol</source> <year>1992</year>; <volume>22</volume>: <fpage>295</fpage>–<lpage>299</lpage>.</citation></ref>
<ref id="bibr15-0961203313478302"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>S</given-names></name><name><surname>Santiago-Raber</surname><given-names>ML</given-names></name><name><surname>Amano</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus</article-title>. <source>J Immunol</source> <year>2006</year>; <volume>176</volume>: <fpage>3240</fpage>–<lpage>3247</lpage>.</citation></ref>
<ref id="bibr16-0961203313478302"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Granholm</surname><given-names>NA</given-names></name><name><surname>Cavallo</surname><given-names>T</given-names></name></person-group>. <article-title>Bacterial lipopolysaccharide enhances deposition of immune complexes and exacerbates nephritis in BXSB lupus-prone mice</article-title>. <source>Clin Exp Immunol</source> <year>1991</year>; <volume>85</volume>: <fpage>270</fpage>–<lpage>277</lpage>.</citation></ref>
<ref id="bibr17-0961203313478302"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lemarie</surname><given-names>A</given-names></name><name><surname>Morzadec</surname><given-names>C</given-names></name><name><surname>Bourdonnay</surname><given-names>E</given-names></name><name><surname>Fardel</surname><given-names>O</given-names></name><name><surname>Vernhet</surname><given-names>L</given-names></name></person-group>. <article-title>Human macrophages constitute targets for immunotoxic inorganic arsenic</article-title>. <source>J Immunol</source> <year>2006</year>; <volume>177</volume>: <fpage>3019</fpage>–<lpage>3027</lpage>.</citation></ref>
<ref id="bibr18-0961203313478302"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goussetis</surname><given-names>DJ</given-names></name><name><surname>Altman</surname><given-names>JK</given-names></name><name><surname>Glaser</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide</article-title>. <source>J Biol Chem</source> <year>2010</year>; <volume>285</volume>: <fpage>29989</fpage>–<lpage>29997</lpage>.</citation></ref>
<ref id="bibr19-0961203313478302"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ondrousková</surname><given-names>E</given-names></name><name><surname>Soucek</surname><given-names>K</given-names></name><name><surname>Horváth</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Alternative pathways of programmed cell death are activated in cells with defective caspase-dependent apoptosis</article-title>. <source>Leuk Res</source> <year>2008</year>; <volume>32</volume>: <fpage>599</fpage>–<lpage>609</lpage>.</citation></ref>
<ref id="bibr20-0961203313478302"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>CO</given-names></name><name><surname>Zang</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice</article-title>. <source>J Immunol</source> <year>2003</year>; <volume>171</volume>: <fpage>1564</fpage>–<lpage>1571</lpage>.</citation></ref>
<ref id="bibr21-0961203313478302"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chowdhary</surname><given-names>VR</given-names></name><name><surname>Crowson</surname><given-names>CS</given-names></name><name><surname>Poterucha</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Liver involvement in systemic lupus erythematosus: Case review of 40 patients</article-title>. <source>J Rheumatol</source> <year>2008</year>; <volume>35</volume>: <fpage>2159</fpage>–<lpage>2164</lpage>.</citation></ref>
<ref id="bibr22-0961203313478302"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pistiner</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>DJ</given-names></name><name><surname>Nessim</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Lupus erythematosus in the 1980s: A survey of 570 patients</article-title>. <source>Semin Arthritis Rheum</source> <year>1991</year>; <volume>21</volume>: <fpage>55</fpage>–<lpage>64</lpage>.</citation></ref>
<ref id="bibr23-0961203313478302"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tzang</surname><given-names>BS</given-names></name><name><surname>Chiang</surname><given-names>SY</given-names></name><name><surname>Lai</surname><given-names>WX</given-names></name><etal/></person-group>. <article-title>Treatment with cystamine reduces apoptosis in liver from NZB/W F1 mice</article-title>. <source>Int Immunopharmacol</source> <year>2008</year>; <volume>8</volume>: <fpage>589</fpage>–<lpage>596</lpage>.</citation></ref>
<ref id="bibr24-0961203313478302"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yap</surname><given-names>DY</given-names></name><name><surname>Lai</surname><given-names>KN</given-names></name></person-group>. <article-title>Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: From basics to recent advances</article-title>. <source>J Biomed Biotechnol</source> <year>2010</year>; <volume>2010</volume>: <fpage>1</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr25-0961203313478302"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>T</given-names></name></person-group>. <article-title>Interleukin 6 and its receptor: Ten years later</article-title>. <source>Int Rev Immunol</source> <year>1998</year>; <volume>16</volume>: <fpage>249</fpage>–<lpage>284</lpage>.</citation></ref>
<ref id="bibr26-0961203313478302"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takemura</surname><given-names>T</given-names></name><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Cellular localization of inflammatory cytokines in human glomerulonephritis</article-title>. <source>Virchows Arch</source> <year>1994</year>; <volume>424</volume>: <fpage>459</fpage>–<lpage>464</lpage>.</citation></ref>
<ref id="bibr27-0961203313478302"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cash</surname><given-names>H</given-names></name><name><surname>Relle</surname><given-names>M</given-names></name><name><surname>Menke</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>60</fpage>–<lpage>70</lpage>.</citation></ref>
<ref id="bibr28-0961203313478302"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>HR</given-names></name><name><surname>Chused</surname><given-names>TM</given-names></name><name><surname>Smathers</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Evidence for thymic regulation of autoimmunity in BXSB mice: acceleration of disease by neonatal thymectomy</article-title>. <source>J Immunol</source> <year>1983</year>; <volume>130</volume>: <fpage>1200</fpage>–<lpage>1204</lpage>.</citation></ref>
<ref id="bibr29-0961203313478302"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>OP</given-names></name><name><surname>Ryu</surname><given-names>M</given-names></name><name><surname>Kantner</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice</article-title>. <source>Nephrol Dial Transplant</source> <year>2012</year>; <volume>27</volume>: <fpage>1358</fpage>–<lpage>1367</lpage>.</citation></ref>
<ref id="bibr30-0961203313478302"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>N</given-names></name><name><surname>Ussin</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>TNFalpha inhibition in MRL/lpr mice ameliorates pulmonary but not renal disease</article-title>. <source>J Autoimmun</source> <year>2002</year>; <volume>19</volume>: <fpage>215</fpage>–<lpage>222</lpage>.</citation></ref>
</ref-list>
</back>
</article>